VERA · Vera Therapeutics, Inc.
$36.82
+1.54 (+4.37%)
At close · Aug 26
Market Cap
$2.65B
Shares
72.06M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Marshall Fordyce | President and Chief Executive Officer | $6,986,410 |
| David Johnson | Chief Operating Officer | $2,721,412 |
| Robert Brenner | Chief Medical Officer | $2,719,852 |
| Sean Grant | Chief Financial Officer | $2,716,732 |
| William Turner | Chief Regulatory Officer | $2,346,180 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jason Carter | Chief Legal Officer | $5,649,923 |
| Marshall Fordyce | President and Chief Executive Officer | $5,648,201 |
| Robert Brenner | Chief Medical Officer | $4,445,802 |
| David Johnson | Chief Operating Officer | — |
| William Turner | Chief Regulatory Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Marshall Fordyce | President and Chief Executive Officer | $3,429,733 |
| Sean Grant | Chief Financial Officer | $1,761,820 |
| Celia Lin | Former Chief Medical Officer | $1,020,673 |
| William Turner | Chief Regulatory Officer | — |
| Robert Brenner | Chief Medical Officer | — |
| David Johnson | Chief Operating Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Marshall Fordyce | President and Chief Executive Officer | $4,106,629 |
| Sean Grant | Chief Financial Officer | $2,475,143 |
| Celia Lin | Former Chief Medical Officer | $1,585,950 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Sean Grant | Chief Financial Officer | $2,082,371 |
| Marshall Fordyce | President and Chief Executive Officer | $1,485,701 |
| Celia Lin | Chief Medical Officer | $1,443,597 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Marshall Fordyce | President and Chief Executive Officer | $3,226,305 |
| Celia Lin | Chief Medical Officer | — |
| Sean Grant | Chief Financial Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Nancy Bowman, M.D., Ph.D. | Chief Regulatory Officer | Appointed | 2026-07-09 |
| William Turner | Special Advisor for Regulatory Affairs | Appointed | 2026-07-09 |
| Christopher Hite | Class III Director | Appointed | 2026-03-09 |
| Jason Carter | Chief Legal Officer | Resigned | 2025-12-18 |
| James R. Meyers | Class II Director | Appointed | 2025-11-26 |
| David Johnson | Chief Operating Officer | Appointed | 2024-07-02 |
| Christy Oliger | Class III Director | Appointed | 2024-06-12 |
| Robert M. Brenner, M.D. | Chief Medical Officer | Appointed | 2024-01-08 |
| William D. Turner | Chief Development Officer | Appointed | 2024-01-08 |
| Michael M. Morrissey, Ph.D. | director | Appointed | 2022-04-12 |
| Michael M. Morrissey, Ph.D. | Chair of the Board | Appointed | 2022-04-12 |
| Kurt von Emster | director | Resigned | 2022-04-12 |
| Kurt von Emster | Chair of the Board | Resigned | 2022-04-12 |
| Kimball Hall | Class I director | Appointed | 2021-12-15 |
| Jonathan Wolter | Chief Financial Officer | Resigned | 2021-07-14 |
| Sean P. Grant | Chief Financial Officer | Appointed | 2021-07-14 |
Key facts
CIK
1831828
CUSIP
92337R101
13F (30d)
202 filings
199 filers
Visit website
Investor relations